<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-140611</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Preoperative management of anemia in oncologic surgery</dc:title>
<dc:description xml:lang="en">Preoperative anemia in patients with cancer is highly prevalent, is associated with increased perioperative morbidity and is a risk factor for transfusion. There is evidence that patients who undergo transfusions have higher morbidity, increased cancer recurrence and poorer survival. The pathophysiology of anemia is multifactorial, with an inflammatory component to which chronic blood loss and nutritional deficiencies can be associated. Therefore, preoperative anemia in patients with cancer should be treated appropriately, given that there is sufficient time in the preoperative period. Of the currently available options, parenteral iron is an effective alternative, especially for those types of cancer that have an associated hemorrhagic component (AU)</dc:description>
<dc:creator>García-Gregorio, N</dc:creator>
<dc:creator>Díaz-Cambronero, O</dc:creator>
<dc:creator>García-Claudio, N</dc:creator>
<dc:creator>Matoses-Jaén, S</dc:creator>
<dc:creator>Molins-Espinosa, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La anemia preoperatoria en los pacientes oncológicos es muy prevalente, se asocia a mayor morbilidad perioperatoria y es un factor de riesgo de transfusión. Existe evidencia de que los pacientes transfundidos tienen mayor morbilidad, mayor recurrencia del cáncer y peor supervivencia. La fisiopatología de la anemia es multifactorial, con un componente inflamatorio al que se puede asociar pérdidas hemáticas crónicas y deficiencias nutricionales. Por ello, la anemia preoperatoria en pacientes con cáncer debería tratarse adecuadamente, ya que se dispone de tiempo suficiente en el preoperatorio. De las opciones disponibles actualmente, el hierro parenteral es una alternativa eficaz, sobre todo en los tipos de cáncer que asocian un componente hemorrágico (AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;62(supl.1): 45-51, jun. 2015. ilus</dc:source>
<dc:identifier>ibc-140611</dc:identifier>
<dc:title xml:lang="es">Manejo preoperatorio de la anemia en cirugía oncológica</dc:title>
<dc:subject>^d7668^s22073</dc:subject>
<dc:subject>^d54247</dc:subject>
<dc:subject>^d755^s22080</dc:subject>
<dc:subject>^d14308^s22054</dc:subject>
<dc:subject>^d53702</dc:subject>
<dc:subject>^d7668^s22000</dc:subject>
<dc:subject>^d7668^s22044</dc:subject>
<dc:subject>^d31478</dc:subject>
<dc:subject>^d755^s22032</dc:subject>
<dc:subject>^d7668^s22015</dc:subject>
<dc:subject>^d9562^s22059</dc:subject>
<dc:subject>^d5009</dc:subject>
<dc:subject>^d9562^s22009</dc:subject>
<dc:subject>^d755^s22016</dc:subject>
<dc:subject>^d286</dc:subject>
<dc:subject>^d1831</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d22198^s22002</dc:subject>
<dc:subject>^d55027</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
